Decreased progesterone levels and progesterone receptor antagonists promote apoptotic cell death in bovine luteal cells.
We tested the hypothesis that progesterone (P(4)) acts at a local level to inhibit luteal apoptosis. Initial experiments employed aminoglutethimide, a P450 cholesterol side-chain cleavage inhibitor, to inhibit steroid synthesis. Cultured bovine luteal cells were treated with aminoglutethimide (0.15 mM) +/- P(4) (500 ng/ml) for 48 h. Luteal cells were recovered and snap frozen for isolation and analysis of oligonucleosomal DNA fragmentation or fixed for morphological analysis. Medium was collected for analysis of P(4) levels by RIA. Aminoglutethimide inhibited P(4) synthesis by > 95% and increased the level of apoptosis as evidenced by (32)P-labeled oligonucleosomal DNA fragmentation (> 40%). P(4) supplementation inhibited the onset of apoptosis that was induced by aminoglutethimide. These data were further supported by morphological assessment of apoptotic cells utilizing a Hoechst staining technique and together strongly suggest that P(4) has anti-apoptotic capacity. Using reverse transcription-polymerase chain reaction, we were able to isolate a 380-base pair cDNA from the bovine corpus luteum (CL) that was 100% homologous to the progesterone receptor (PR) previously found in bovine oviductal tissue. Furthermore, PR transcripts were present in large and small luteal cells. Immunohistochemistry also revealed that PR protein was present in both large and small luteal cells. To determine whether the anti-apoptotic effect of P(4) was regulated at the receptor level, luteal cells were cultured in the presence of PR antagonists, RU-486 and onapristone, for 48 h. Both antagonists caused approximately a 40% increase in (32)P-labeled oligonucleosomal DNA fragmentation. Interestingly, there was no difference (P >/= 0.05) in P(4) levels after treatment with PR antagonists. These observations support the concept that P(4) represses the onset of apoptosis in the CL by a PR-dependent mechanism.
Rueda
B R
BR
The Women's Research Institute, Wichita, Kansas 67214, USA. brueda@kumc.edu
Hendry
I R
IR
Hendry III
W J
WJ
Stormshak
F
F
Slayden
O D
OD
Davis
J S
JS
D000616:Aminoglutethimide / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D002417:Cattle; D003338:Corpus Luteum / Q000166:cytology* / Q000187:drug effects; D065607:Cytochrome P-450 Enzyme Inhibitors; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006067:Gonanes / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology; D007150:Immunohistochemistry; D015735:Mifepristone / Q000494:pharmacology; D011374:Progesterone / Q000502:physiology*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D011863:Radioimmunoassay; D011980:Receptors, Progesterone / Q000037:antagonists & inhibitors*; D013256:Steroids / Q000096:biosynthesis
D065607:Cytochrome P-450 Enzyme Inhibitors; D018076:DNA, Complementary; D004791:Enzyme Inhibitors; D006067:Gonanes; D006727:Hormone Antagonists; D012333:RNA, Messenger; D011980:Receptors, Progesterone; D013256:Steroids; D000616:Aminoglutethimide; D015735:Mifepristone; D011374:Progesterone; C053238:onapristone